bufalin (Compound)

Synonyms:bufalin, 465-21-4, CHEBI:517248, 3-beta,14-Dihydroxy-5-beta-bufa-20,22-dienolide, 3,14-Dihydroxy-bufa-20,22-dienolide, U549S98QLW, 5-((3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2H-pyran-2-one, 3beta,14beta-dihydroxy-5beta-bufa-20,22-dienolide, 5-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one, UNII-U549S98QLW, NSC-89595, Ch'an su, BUF, NSC 89595, BRN 5141601, BUFALIN [MI], (3beta,5beta)-3,14-dihydroxybufa-20,22-dienolide, BUFALIN [WHO-DD], SCHEMBL165666, Bufa-20,22-dienolide, 3,14-dihydroxy-, (3.beta.,5.beta.)-, CHEMBL399680, Bufa-20,22-dienolide, 3,14-dihydroxy-, (3b,5b)-, DTXSID90873563, AMY40632, Bufalin: Bufa-20,22-dienolide, 3,14-dihydroxy-, (3b,5b)-,, HY-N0877, BDBM50584761, HSCI1_000110, LMST01130001, MFCD30207876, s7821, AKOS015965454, CS-3694, SMP2_000290, AC-20197, AC-34068, BS-17080, C16922, 5beta-Bufa-20,22-dienolide, 3beta,14-dihydroxy-, BRD-K63606607-001-01-8, BRD-K63606607-001-02-6, Q18379323, 5-beta-BUFA-20,22-DIENOLIDE, 3-beta,14-DIHYDROXY-, Bufa-20,22-dienolide, 3,14-dihydroxy-, (3beta,5beta)-, Bufa-20,22-dienolide, 3,14-dihydroxy-, (3-beta,5-beta)-
Pubchem:PUBCHEM:9547215
Id:d95230b7-46ab-5ea7-9647-595906e43d50
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View bufalin's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for bufalin.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with bufalin.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.